Research location

New Orleans

Louisiana, United States

Published trials1,617

Site observations2,145

Linked trials published1,617

Page2 / 33

Research activity in New Orleans

Louisiana, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 1,617 trials and 2,145 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in New Orleans

1,617 linked trials · page 2 of 33

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNCT06228326 · 2024-04-17 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsNCT06112418 · 2024-03-06 · 1 site observation

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationNCT05806515 · 2024-03-01 · 1 site observation

Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in LouisianaNCT05676970 · 2024-01-01 · 1 site observation

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsNCT06223880 · 2023-12-27 · 1 site observation

Vitamin D for Prostate Endocrine TherapyNCT05838716 · 2023-12-14 · 3 site observations

Strategies for Implementing a Postpartum Lifestyle Intervention in WIC ClinicsNCT06116149 · 2023-12-12 · 1 site observation

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer CachexiaNCT06073431 · 2023-12-04 · 1 site observation

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 2 site observations

CtDNA Based MRD Testing for NAC Monitoring in TNBCNCT06230185 · 2023-11-09 · 1 site observation

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)NCT06133322 · 2023-11-01 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 4 site observations

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 2 site observations

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerNCT05803941 · 2023-08-14 · 2 site observations

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 DiabetesNCT05762107 · 2023-07-28 · 1 site observation

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 3 site observations

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 3 site observations

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17 · 1 site observation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 2 site observations

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.NCT05676476 · 2023-02-14 · 1 site observation

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support InterventionNCT05723653 · 2023-02-13 · 1 site observation

Alleviant ALLAY-HF StudyNCT05685303 · 2023-01-10 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 2 site observations

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVNCT05266898 · 2022-11-30 · 1 site observation

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 2 site observations

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab ClassifierNCT06426628 · 2022-07-18 · 1 site observation

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaNCT05235165 · 2022-04-01 · 2 site observations

AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEMNCT06378632 · 2022-02-11 · 1 site observation

Assessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03 · 1 site observation

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444 · 2021-09-07 · 1 site observation

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 4 site observations

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)NCT06719583 · 2020-11-16 · 1 site observation

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 4 site observations

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)NCT04278404 · 2020-03-05 · 2 site observations

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542 · 2020-03-04 · 1 site observation

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 3 site observations

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 3 site observations

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 2 site observations

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25 · 1 site observation

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryNCT03452774 · 2018-01-01 · 1 site observation

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMRNCT03142152 · 2018-01-01 · 1 site observation

New Orleans Pulmonary Hypertension BiobankNCT03269630 · 2017-12-29 · 1 site observation

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection FractionNCT02901184 · 2017-11-23 · 1 site observation

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation

International Registry for Men With Advanced Prostate Cancer (IRONMAN)NCT03151629 · 2017-07-21 · 1 site observation

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsNCT03093116 · 2017-03-07 · 1 site observation

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)NCT02620852 · 2016-08-31 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.